

## 8. Administration of tarlatamab-dlle \*\*

## 9. Intraoperative Donor Organ

Protection in Renal Transplantation

## 10. Section X Updates

## 11. Addenda and Key Updates \*

\* Request is for an April 1, 2025, implementation date.

\*\* Request is for an April 1, 2025, implementation date, and the requestor intends to submit a new technology add-on payment (NTAP) application for FY 2026 consideration.

\*\*\* Requestor intends to submit an NTAP application for FY 2026 consideration.

Presentations for procedure code requests are conducted by both the requestor and the Centers for Medicare & Medicaid Services (CMS) during the C&M Committee meeting. Discussion from the requestor generally focuses on the clinical issues for the procedure or technology, followed by the proposed coding options from a CMS analyst. Topics presented may also include requests for new procedure codes that relate to a new technology add-on payment (NTAP) policy request.

CMS has modified the approach for presenting the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent. For the September 10-11, 2024, ICD-10 C&M Committee meeting, consistent with the requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the ICD-10-PCS procedure code classification. CMS will initially display only those meeting materials associated with the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent on the CMS website in August 2024 at: <https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials>.

The NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent are:

1. Administration of emapalumab-lzsg \*\*
2. Administration of tarlatamab-dlle \*\*

\*\* Request is for an April 1, 2025, implementation date, and the requestor intends to submit an NTAP application for FY 2026 consideration..

These topics will not be presented during the September 10-11, 2024, meeting. CMS will solicit public

comments regarding any clinical questions or coding options included for these procedure code topics in advance of the meeting continuing through the end of the respective public comment periods. Members of the public should send any questions or comments to the CMS mailbox at:

[ICDProcedureCodeRequest@cms.hhs.gov](mailto:ICDProcedureCodeRequest@cms.hhs.gov).

CMS intends to post a question-and-answer document in advance of the meeting to address any clinical or coding questions that members of the public may have submitted. Following the conclusion of the meeting, CMS will post an updated question-and-answer document to address any additional clinical or coding questions that members of the public may have submitted during the meeting that CMS was not able to address or that were submitted after the meeting.

The NTAP-related ICD-10-PCS procedure code requests that do not involve the administration of a therapeutic agent and all non-NTAP-related procedure code requests will continue to be presented during the virtual meeting on September 10, 2024, consistent with the standard meeting process.

CMS will make all meeting materials and related documents available at: <https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials>. Any inquiries related to the procedure code topics scheduled for the September 10-11, 2024, ICD-10 C&M Committee meeting that are under consideration for April 1, 2025, or October 1, 2025, implementation should be sent to the CMS mailbox at: [ICDProcedureCodeRequest@cms.hhs.gov](mailto:ICDProcedureCodeRequest@cms.hhs.gov).

## ICD-10-CM Topics:

1. Abnormal Rheumatoid Factor and Anti-citrullinated Protein Antibody Without a Diagnosis of Rheumatoid Arthritis
2. Demodex Blepharitis
3. Encounter for Prophylactic Removal of Fallopian Tube(s) for Persons Without Known Genetic/Familial Risk Factors
4. Genetic Neurodevelopmental Disorders
5. Hypothalamic Obesity
6. Kabuki Syndrome
7. Topical Steroid Withdrawal
8. Usher Syndrome
9. Addenda

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been

delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024-15795 Filed 7-17-24; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention****Safety and Occupational Health Study Section; Notice of Charter Renewal**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of charter renewal.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the renewal of the charter of the Safety and Occupational Health Study Section (SOHSS).

**FOR FURTHER INFORMATION CONTACT:** Joanne Fairbanks, Designated Federal Officer, Safety and Occupational Health Study Section, Centers for Disease Control and Prevention, Department of Health and Human Services, 1095 Willowdale Road, Morgantown, West Virginia 26505. Telephone: (304) 285-6143; Email: [JFairbanks@cdc.gov](mailto:JFairbanks@cdc.gov).

**SUPPLEMENTARY INFORMATION:** CDC is providing notice under 5 U.S.C. 1001 through 1014 of the renewal of the charter of the Safety and Occupational Health Study Section, Centers for Disease Control and Prevention, Department of Health and Human Services. This charter has been renewed for a two-year period through June 30, 2026.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2024–15796 Filed 7–17–24; 8:45 am]

BILLING CODE 4163–18–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Meeting of the Board of Scientific Counselors, National Center for Injury Prevention and Control**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Board of Scientific Counselors, National Center for Injury Prevention and Control (BSC, NCIPC). This meeting is open to the public. Time will be available for public comment.

**DATES:** The meeting will be held on September 24, 2024, from 10 a.m. to 12:30 p.m., EDT. The public comment period will be from 12:10 p.m. to 12:25 p.m., EDT.

**ADDRESSES:** Webinar, Atlanta, Georgia. All participants must register by using the following link to attend the meeting: [https://cdc.zoomgov.com/webinar/register/WN\\_cnG74hSRR8C\\_2DCCRmW5Hg](https://cdc.zoomgov.com/webinar/register/WN_cnG74hSRR8C_2DCCRmW5Hg).

**FOR FURTHER INFORMATION CONTACT:** Christopher R. Harper, Ph.D., Designated Federal Officer, Board of Scientific Counselors, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S–1069, Atlanta, Georgia 30341. Telephone: (404) 718–8330; Email: [ncipcbsc@cdc.gov](mailto:ncipcbsc@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

*Purpose:* The Board of Scientific Counselors, National Center for Injury Prevention and Control (BSC, NCIPC) will: (1) conduct, encourage, cooperate with, and assist other appropriate public health authorities, scientific institutions, and scientists in the conduct of research, investigations, experiments, demonstrations, and studies relating to the causes and

strategies related to the prevention of injury, overdose, and violence; (2) assist States and other entities in preventing intentional and unintentional injuries, and to promote health and well-being; and (3) make recommendations of grants and cooperative agreements for research and prevention activities related to injury, overdose, and violence. The BSC, NCIPC makes recommendations regarding policies, strategies, objectives, and priorities and reviews progress toward injury, overdose, and violence prevention. The Board also provides advice on the appropriate balance of intramural and extramural research and provides guidance on the needs, structure, progress, and performance of intramural programs. Further, the Board provides guidance on extramural scientific program matters. Additionally, the Board provides second-level scientific and programmatic review of applications for research grants, cooperative agreements, and training grants related to injury, overdose, and violence prevention, and recommends approval of projects that merit further consideration for funding support. The Board also provides feedback and input on strategic plans, resources, and priority publications related to injury, overdose, and violence prevention.

*Matters to be Considered:* The agenda will include discussions on the Updated Child Abuse and Neglect Research Priorities and the Updated Youth and Community Violence Research Priorities. Agenda items are subject to change as priorities dictate.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2024–15793 Filed 7–17–24; 8:45 am]

BILLING CODE 4163–18–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[Docket No. CDC–2024–0055; NIOSH 232]

**Meeting of the Board of Scientific Counselors, National Institute for Occupational Safety and Health, National Firefighter Registry Subcommittee**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH), National Firefighter Registry Subcommittee. This meeting will take place in person and virtually. It is open to the public, limited only by the space available (approximately 80 seats) and the number of web conference lines available (500 lines). Time will be available for public comment.

**DATES:** The meeting will be held on August 22, 2024, from 9 a.m. to 3:30 p.m., EDT.

Written comments must be received on or before August 15, 2024.

**ADDRESSES:** Centers for Disease Control and Prevention, Alice Hamilton Laboratory Building, 5555 Ridge Avenue, Cincinnati, Ohio 45213. The conference room will have seating for approximately 80 people.

Please note that the meeting location is a Federal facility and in-person access is limited to United States citizens unless prior authorizations, taking up to 30 to 60 days, have been made. Visitors must follow all directions for access to CDC facilities. Instructions for visitors to CDC, including safety requirements related to COVID–19, are available at <https://www.cdc.gov/screening/visitors.html>.

If you wish to attend the meeting either in person or virtually, please register at the NIOSH website at <https://www.cdc.gov/niosh/scientific-counselors/nfrs.html> or by telephone at (404) 498–1650 no later than August 15, 2024. If you are attending virtually, you will receive the Zoom web conference access information after registering.

You may submit comments, identified by Docket No. CDC–2024–0055;